Health-related quality of life in genotype 1 treatment-naïve chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study

Autor:	J. Aggarwal, M. Martin, T. Goss, Zobair M. Younossi, Martha S. Bayliss, Mrudula Donepudi, Montserrat Vera-Llonch
Rok vydání:	2013
Předmět:	Adult Male medicine.medical_specialty Time Factors Multivariate analysis Genotype Health Status Hepacivirus Antiviral Agents Polyethylene Glycols Telaprevir law.invention chemistry.chemical_compound Randomized controlled trial Quality of life law Surveys and Questionnaires Internal medicine Ribavirin medicine Humans Pharmacology (medical) Prospective Studies Prospective cohort study Hepatology business.industry Minimal clinically important difference Gastroenterology Interferon-alpha Hepatitis C Hepatitis C Chronic Middle Aged Viral Load medicine.disease Recombinant Proteins chemistry Area Under Curve Quality of Life Physical therapy Drug Therapy Combination Female business Oligopeptides medicine.drug
Zdroj:	Alimentary Pharmacology & Therapeutics. 38:124-133
ISSN:	0269-2813
DOI:	10.1111/apt.12354
Popis:	Summary Background Chronic hepatitis C virus (HCV) infection and its treatment impact patients' health-related quality of life (HRQL). Aim To report on treatment impact and predictors of HRQL among treatment-naive patients with genotype 1 chronic HCV infection who received 12-week telaprevir (T) with 24 (T12PR24) or 48 weeks (T12PR48) peginterferon alpha-2a/ribavirin (PR), or 48 weeks of PR in the ADVANCE study. Methods The EQ-5D-3L (EQ-5D) questionnaire (index range: 0–1) was completed at baseline and weeks 4, 12, 24, 36, 48 and 72. Patients indicated their health state on five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Descriptive statistics for the EQ-5D index and descriptive system and area under the curve from baseline to week 12 were calculated. Predictors of EQ-5D index were identified using multivariate analyses. Results Data from 722 patients were included. The mean EQ-5D index decreased during the first 12 weeks and returned to baseline by week 72 (T12PR24 by week 36) across treatments. In multivariate analysis, sustained virological response (SVR) at week 72 was associated (P
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f0a25faf2d7f3af421f3f5ce88b7ea6 https://doi.org/10.1111/apt.12354 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.